(CercleFinance.com) – Genomic Vision announced on Tuesday that it has entered into a technological agreement with The Institute of Cancer Research, a cancer research institute based in London.
Under the terms of the partnership, Genomic will provide the academic institution with its state-of-the-art fluorescence scanner for molecular combing, FiberVisionS, as well as its advanced AI algorithm FiberSmart.
The agreement with ICR, known for its expertise in oncology drug discovery, includes a one-time upfront payment with the possibility of additional recurring revenue from the sale of consumables, the biotech company says.
Following this order, Genomic Vision shares were up 1.5% on Tuesday on the Paris Stock Exchange.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
